BioTuesdays Feature Articles | Life Sciences News

Feature

Monogram next gen robot seeks to disrupt orthopedic market

Monogram Orthopedics (NASDAQ:MGRM) is working to advance the standard of care with its next-generation robot and 3D-printed implants that match a patient's precise anatomy, decreasing the number of incisions and bone...

July 11, 2023

Feature

Cantex’s azeliragon in cancer, prevention of acute kidney injury trials

Closely-held Cantex Pharmaceuticals has an extensive Phase 2 program underway with its lead drug candidate, azeliragon, in breast cancer, pancreatic cancer, brain metastasis and glioblastoma, well as in prevention of...

July 4, 2023

Feature

Chinook on a mission to change the course of kidney care

Chinook Therapeutics (NASDAQ:KDNY), which is developing three drug candidates to change the course of kidney care as well as a precision medicine pipeline of R&D programs, received a shot in the arm this month when...

June 27, 2023

Feature

Centessa focused on asset-centric, patient-centric drug development

Centessa Pharmaceuticals (NASDAQ:CNTA) is developing a portfolio of innovative drug candidates with small, focused R&D teams, a model it calls “asset-centric.”

June 20, 2023

Feature

ZyVersa developing multiple drug therapies in renal, inflammatory diseases

ZyVersa Therapeutics (NASDAQ: ZVSA) is advancing two proprietary technologies to develop multiple, potentially transformative drugs for underserved patients with renal and inflammatory diseases.

June 13, 2023

Feature

Avivo developing universal donor blood type to expand transplants, safer transfusions

John Coleman, Ph.D., envisions a future where blood types cease to be a primary constraint in life-saving organ transplants and blood transfusions. “Recognizing the urgent need for solutions to these challenges, we have...

June 6, 2023

Feature

Virax Biolabs readies clinical performance study of ViraxImmune Platform

Virax Biolabs (NASDAQ:VRAX) expects to begin in the third quarter a clinical performance study of its proprietary T-Cell testing platform, ViraxImmune, as a stepping stone for regulatory compliance in the U.S. and...

May 30, 2023

Feature

HDT Bio focused on global impact of mRNA vaccine platform

HDT Bio is developing messenger RNA vaccines addressing diverse indications in infectious diseases and oncology, and is utilizing regional partnerships for manufacturing, clinical development and commercialization.

May 23, 2023

Feature

ADvantage Therapeutics taking disruptive approach to mild Alzheimer’s

Closely-held ADvantage Therapeutics is awaiting regulatory approval in Europe to proceed with a Phase 2b confirmatory clinical trial of its lead drug candidate, AD04, for the treatment of mild Alzheimer’s disease (AD).

May 16, 2023

Feature

Peptilogics lead peptide platform targeting serious joint replacement infections

Peptilogics is working to change the treatment paradigm of periprosthetic joint infection (PJI), a serious condition that can result from joint replacement surgery. The company is preparing for a registrational clinical...

May 9, 2023

Feature

SynaptixBio targeting rare disease, TUBB4A leukodystrophy, virtually

UK based biotechnology company SynaptixBio is developing the world’s first life-saving medicine for TUBB4A leukodystrophy, a rare genetic neurodegenerative disease that affects approximately 1,600 newborn babies and...

May 2, 2023

Feature

EyePoint focused on long-lasting treatments for wet AMD and DR

EyePoint Pharmaceuticals (NASDAQ:EYPT) is advancing its lead drug candidate, EYP-1901, in two Phase 2 clinical trials as a potential six-month treatment for wet age-related macular degeneration (AMD) and a potential...

April 25, 2023

Feature

Alaunos attacking solid tumors with cutting-edge TCR-T cell therapies

Alaunos Therapeutics (NASDAQ:TCRT) is developing a library of T-cell receptor (TCR) cell therapies with the potential to revolutionize the treatment of solid tumors.

April 18, 2023

Feature

Rezolute focused on paradigm shift treating DME

Rezolute (NASDAQ:RZLT) is working on therapies targeting both ends of the spectrum of dysregulated glucose. It has now entered Phase 2 with an oral therapy to treat diabetic macular edema (DME), a big market...

April 11, 2023

Feature

KeifeRx developing oral TKIs for neurodegenerative and immune diseases

Closely-held KeifeRx is developing optimized, low dose, oral tyrosine kinase inhibitors (TKIs) for the treatment of multiple neurodegenerative and immune diseases.

April 4, 2023

Feature

BioStem Technologies harnessing perinatal tissue for regenerative therapies

Fresh from a decision by the Center for Medicare Services to establish national pricing for its VENDAJE allografts for regenerative therapies, BioStem Technologies (OTCQB:BSEM) is gearing up for a new spurt of growth.

March 28, 2023

Feature

Enveric taking new approach to mental health challenges

Enveric Biosciences (NASDAQ:ENVB) has created a library of more than 500 new chemical entities from its drug platform, including next generation psilocybin analogues for the treatment of anxiety, depression, and...

March 21, 2023

Feature

bioAffinity rolling out CyPath for early detection of lung cancer

bioAffinity Technologies (NASDAQ:BIAF) is rolling out CyPath Lung, an accurate, non-invasive and cost-effective test for the early detection of lung cancer, in the U.S. Southwest before a staged nationwide launch.

March 14, 2023

Feature

Conavi’s Novasight shines new light on coronary interventions

Privately-held Conavi Medical’s Novasight Hybrid System represents a breakthrough imaging platform for use by interventional cardiologists during common minimally invasive heart procedures.

March 7, 2023

Feature

AUM Biosciences focused on reversing cancer resistance

With two clinical and two preclinical assets, AUM Biosciences is developing precision oncology therapeutics designed to reverse cancer resistance through multi-targeting approaches.

February 28, 2023

Feature

Cognition Therapeutics focused on modifying degenerative disorders

As the recipient of more than $170-million of non-dilutive grant funding, Cognition Therapeutics (NASDAQ:CGTX) is developing disease-modifying medicines for neurodegenerative disorders, such as Alzheimer's disease (AD)...

February 21, 2023

Feature

Context Therapeutics advancing pipeline for female cancers and other tumors

Martin Lehr likes to use a baseball analogy to describe his company’s two cancer programs. “CTIM-76 is our hot young rookie with home run potential at every bat while ONA-XR is our veteran who consistently gets on...

February 14, 2023

Monogram next gen robot seeks to disrupt orthopedic market

Cantex’s azeliragon in cancer, prevention of acute kidney injury trials

Chinook on a mission to change the course of kidney care

Centessa focused on asset-centric, patient-centric drug development

ZyVersa developing multiple drug therapies in renal, inflammatory diseases

Avivo developing universal donor blood type to expand transplants, safer transfusions

Virax Biolabs readies clinical performance study of ViraxImmune Platform

HDT Bio focused on global impact of mRNA vaccine platform

ADvantage Therapeutics taking disruptive approach to mild Alzheimer’s

Peptilogics lead peptide platform targeting serious joint replacement infections

SynaptixBio targeting rare disease, TUBB4A leukodystrophy, virtually

EyePoint focused on long-lasting treatments for wet AMD and DR

Alaunos attacking solid tumors with cutting-edge TCR-T cell therapies

Rezolute focused on paradigm shift treating DME

KeifeRx developing oral TKIs for neurodegenerative and immune diseases

BioStem Technologies harnessing perinatal tissue for regenerative therapies

Enveric taking new approach to mental health challenges

bioAffinity rolling out CyPath for early detection of lung cancer

Conavi’s Novasight shines new light on coronary interventions

AUM Biosciences focused on reversing cancer resistance

Cognition Therapeutics focused on modifying degenerative disorders

Context Therapeutics advancing pipeline for female cancers and other tumors

General

More